Correction
7 Jun 2013: Shiau MY, Fan LC, Yang SC, Tsao CH, Lee H, et al. (2013) Correction: Human Papillomavirus Up-Regulates MMP-2 and MMP-9 Expression and Activity by Inducing Interleukin-8 in Lung Adenocarcinomas. PLOS ONE 8(6): 10.1371/annotation/a50fa759-93fb-444d-9523-9d4a805ef898. https://doi.org/10.1371/annotation/a50fa759-93fb-444d-9523-9d4a805ef898 View correction
Figures
Abstract
Human papillomavirus (HPV) infection is associated with non-smoking female lung cancer. Our previous report demonstrated that HPV 16 promotes lung tumor cell progression by up-regulating interleukin-17 (IL-17). IL-17 and its downstream signaling mediator, interleukin-8 (IL-8), have been implicated to modulate a variety of pro-angiogenic factors and play important roles in tumor angiogenesis and metastasis. Accordingly, we hypothesized that HPV infection may potentiate tumorigenic and metastatic characteristics of the infected cells through IL-8. The goal of the present study was to determine whether HPV infection in lung adenocarcinoma cells can promote the expression of IL-8 and metalloproteinases (MMPs) to make the transformed cells equipped with angiogenic and metastatic characteristics. The expression of IL-8 and MMPs in HPV 16 E6-transfected H1299 cells was analyzed to examine the hypothesis. HPV 16 E6 up-regulates pro-angiogenic MMP-2 and MMP-9 through inducing IL-8 expression in lung cancer cells. The results indicate that, in addition to cell proliferation-related machinery, HPV infection promotes the expression and activities of angiogenic and metastatic molecules in lung adenocarcinoma cells. The cytokines induced by HPV infection may work together to confer the malignant and tumorigenic potentials on the infected cells by promoting machineries of growth, angiogenic and metastatic characteristics.
Citation: Shiau M-Y, Fan L-C, Yang S-C, Tsao C-H, Lee H, Cheng Y-W, et al. (2013) Human Papillomavirus Up-Regulates MMP-2 and MMP-9 Expression and Activity by Inducing Interleukin-8 in Lung Adenocarcinomas. PLoS ONE 8(1): e54423. https://doi.org/10.1371/journal.pone.0054423
Editor: Suminori Akiba, Kagoshima University Graduate School of Medical and Dental Sciences, Japan
Received: September 12, 2012; Accepted: December 11, 2012; Published: January 21, 2013
Copyright: © 2013 Shiau et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by grants from the National Science Council, Taiwan, Republic of China (NSC98-2320-B-010-034-MY3, NSC101-2320-B-010-052-MY3 and NSC100-2320-B-241-003). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Lung cancer is one of the most common causes of cancer death in developed countries. The tumorigenesis and disease progression of lung cancer are a complicated process including cell transformation, evasion of host defenses, angiogenesis, invasion and metastasis. Angiogenesis is not only regulated by a complex interaction among various growth factors and cytokines, but also influenced by proteolytic enzymes such as matrix metalloproteases (MMPs) and distribution of extracellular matrixes [1]. Recent evidence suggests that angiogenesis is related to poor prognosis in lung cancer [2]–[5].
Our previous studies document that human papillomavirus (HPV) infection is associated with non-smoking Taiwanese female lung cancer [6], [7]. The E6 antigens of HPV 16 up-regulate interleukin-6 (IL-6) and anti-apoptotic Mcl-1 which, subsequently, may promote the tumor progression of HPV-infected lung cancer [8]. More recently, we further reveal that CD4+ T cell derived pro-inflammatory cytokine interleukin-17 (IL-17) is elevated in HPV-infected lung adenocarcinoma cells [9]. Evidences show that tumor cell-derived IL-17 may promote in vivo tumor growth and potentiate angiogenesis [10]. The CD4+ T cell derived cytokine IL-17 promotes tumor angiogenesis via not only stimulating vascular endothelial cell migration but also inducing a variety of pro-angiogenic factors, particularly IL-8, that lead to the imbalance between angiogenesis activators and inhibitors within vascular microenvironment [10].
IL-8 is a potent angiogenic factor which is associated with metastasis in several cancers [11]–[14]. Study from Bequet-Romero et al. reported that conditioned media of HPV-positive cells are able to induce pro-angiogenic IL-8 expression that supports tumor growth and invasion in human umbilical vein endothelial cells [15]. They also demonstrated that IL-8 is predominantly detected in lung tumor cells [15] and the elevated IL-8 is correlated with angiogenesis, tumor progression and poor survival in non-small cell lung cancer (NSCLC) [16]–[18]. Tumor-derived IL-8 levels are correlated with the growth rate of human NSCLC cells in SCID mice [19]. In vitro and animal studies [19], [20] show that lung cancer cell proliferation and growth can be inhibited by antagonizing IL-8 effects. Accumulating evidence demonstrates that serum IL-8 levels are not only elevated in patients with advanced NSCLC, but also associated with patients’ clinicopathologic characteristics, angiogenesis, tumor progression and prognosis [16]–[21]. The above findings suggest that biological effects of IL-8 during lung tumorigenesis are mainly promoting angiogenesis. Inone et al. reported that by overexpressing IL-8 in human prostate cancer cells, the concomitantly up-regulated MMP-9 expression and collagenase activities would promote tumor cell growth and metastasis [22]. Furthermore, endothelial cell angiogenesis is promoted under IL-8 treatment through boosting MMP-2 and MMP-9 expression [23]. These results further indicate that regulation of angiogenesis by IL-8 in tumor cells is, at least in part, through induction of MMP-2 and MMP-9 expression.
According to the bioactivity of IL-17 to promote tumorigenesis and the expression of down-stream cytokines as well as the significant correlation between IL-17 expression and HPV infection in lung tumors, we hypothesized that HPV-induced IL-17 may potentiate tumorigenic and metastatic characteristics of the infected cells through its downstream signaling mediator IL-8. Therefore, the present study examined the expression and activity of metastasis-related proteins in HPV-transfected H1299 lung adenocarcinoma cells to verify the above hypothesis. In this regard, pro-angiogenic IL-8, MMP-2, and MMP-9 expressions were examined in HPV 16 E6- transfected H1299 cells. Our results reveal that HPV 16 E6 in H1299 cells can significantly up-regulate pro-angiogenic MMP-2 and MMP-9 through inducing IL-8.
Materials and Methods
Cell Culture and HPV 16 E6 Transfection
Human lung adenocarcinoma H1299 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 supplemented with 10% FBS, 2 mM glutamine, 100 units/mL penicillin, and 100 mg/mL streptomycin (Life Technologies, Inc.) at 37°C and 5% CO2 [9]. Full length E6 of HPV 16 was amplified by PCR from HPV 16 genome-containing CasKi cells as previously described [8]. The resulted PCR products were purified with GENECLEAN III kit (Qbiogene, Irvine, CA, USA) and cloned into a eukaryotic expression vector pIND/V5-His-TOPO (Invitorogen, California, USA). DNA prepared from the resultant recombinants were transfected into H1299. On the day prior to transfection, cells were grown to 80% confluency in RPMI-1640 medium, and the cells were cotrasfected with either pIND/TOPO/lacZ and pVgRXR-verB (H1299-pIND) or pIND/TOPO-HPV 16 E6 and pVgRXR-verB (H1299-HPV16E6) in 40 uL DOTAP Liposomal (Roche Diagnostics GmbH, Mannheim, Germany) and 100 uL HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). The culture media was aspirated, and fresh RPMI-1640 medium was added after 6 hours of incubation, then the transfects were maintained in medium containing 500 ug/mL G418.
RNA Extraction and RT-PCR
Total RNA was isolated using TRIZOL reagent (Life Technologies, Gaithersburg, MD). Briefly, cDNA was synthesized using total RNA (3 ug), oligo dT primer (200 pmol), and 5× MMLV RT. Then the PCR conditions for each target gene were optimized before analysis, with the respective number of PCR amplification cycle, annealing temperature and primer sets listed in Table 1. All RT-PCR reactions of target genes were carried out with BIO-RAD PCR iCYCLER. Amplified products were identified by electrophoresis and then stained with ethidium bromide.
Western Blot Analysis
Cell lysates were harvested using protease inhibitor-containing lysis buffer (50 mM Tris, 0.1% Triton X-100, 107 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 ug/uL apotinin and 10 ug/mL leupeptin, pH 7.5) and quantitated by using Bio-Rad Bradford protein assay kit. Equal amounts of proteins (30 ug/lane) were separated on 12% SDS-PAGE and electrotransfered to PVDF membranes. The membranes were blocked with 1× Tris buffered saline-Tween buffer (TTBS; 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) containing 5% skim milk and then probed with primary antibody for HPV-C1P5 (Santa Cruz, CA, USA), IL-8 (Santa Cruz, CA, USA), and ß-actin (Sigma), respectively. The membrane was then washed 3 times and incubated with secondary antibody conjugated with HRP for 90 min at room temperature. After washing 5 times with TTBS, the membrane was developed with enhanced chemiluminescence kit (ECL kit, Amersham Biosciences, Piscataway, NJ, USA). ß-actin in all of the samples was probed to exclude false-negative results.
Zymography
Culture media were harvested after parental H1299, H1299-pIND and H1299-HPV16E6 cells were cultured in serum-free RPMI 1640 with or without 5 uM ponasterone A (PonA) and 100% alcohol (Alc), respectively, for 24 hours. The activities of MMP-2 and MMP-9 in the collected media were measured as previously described [24]. Briefly, samples were prepared with standard SDS-gel-loading buffer containing 0.01% SDS without ß-mercaptoethanol and heating. The prepared samples were subjected to electrophoresis with 8% SDS-PAGE containing 0.1% gelatin. Following electrophoresis, the gels were washed in 2.5% Triton X-100 at room temperature to remove SDS, incubated in 100 mL reaction buffer (40 mM Tris-HCl, pH 8.0, 10 mM CaCl2, 0.02% NaN3) for 24 h at 37°C and stained with Coomassie brilliant blue R-250 containing 50% methanol and 10% acetic acid. Gelatinolytic activities were visualized by negative staining with 20% methanol and 10% acetic acid. Clear bands indicated gelatinolytic activities were present at the expected molecular weight for MMP-2 and MMP-9.
Enzyme-linked Immunosorbent Assay
Culture media were harvested after parental H1299, H1299-pIND and H1299-HPV16E6 cells were cultured in serum-free RPMI 1640 with or without 5 uM PonA and 100% Alc for 24 hours, respectively. Cell-free supernatants were collected and stored at −20°C until analysis. Levels of IL-8, MMP-2 and MMP-9 were measured by ELISA kits (R&D Systems).
Results
IL-8 Expression is Up-regulated in HPV 16 E6-transfected H1299 Cells
The study started with establishing HPV-transfected H1299 lung adenocarcinoma cells for the purpose of investigating the effects of HPV infection on IL-8 expression. HPV 16 E6 RNA and protein levels were analyzed in parental H1299 cells, control vector-transfected H1299 cells (H1299-pIND) and full-length HPV 16 E6-transfected H1299 cells (H1299-HPV16E6). As shown in Figure 1, HPV 16 E6 expression could not be detected in parental H1299 and H1299-pIND cells. On the contrary, both the expression of HPV 16 E6 RNA (Fig. 1A) and proteins (Fig. 1B) were highly induced upon the treatment of inducing agent PonA, compared with the Alc-treated counterparts. Therefore, HPV 16 E6 expression could be successfully controlled by using this induction system.
HPV 16 E6 expression levels of H1299-HPV16E6 induced by 5 µM ponasterone A (PonA) was significantly higher than that of parental H1299, H1299-pIND and H1299-HPV16E6 treated with 100% alcohol (Alc) or PonA after 24 hours. (A) RNA was isolated and subjected to RT-PCR analysis using specific primers to HPV 16 E6 and GAPDH. (B) Total cell extracts were used to detect HPV 16 E6 and β-actin by Western blot analysis. HPV 16 E6-containing SiHa cervical cancer cells were used as positive control (lane 10).
The putative effects of HPV infection on IL-8 expression were subsequently analyzed. As shown in Figure 2A, IL-8 RNA expression was significantly up-regulated in H1299-HPV16E6 cells upon PonA treatment. IL-8 secretion of the parental H1299 cells and H1299-pIND, either in the presence of PonA or Alc treatment, was approximately 65 pg/mL (Fig. 2B and Table S1). Notably, the IL-8 levels of H1299-HPV16E6 were dramatically elevated about 2.5 folds in E6 transfectants by PonA stimulation (270.59±19.88 pg/mL; Figure 2B and Table S1). Whereas, the IL-8 levels of the E6 transfectant without inducing agent and under Alc treatment was 117.10±15.24 pg/mL and 165.53±13.10 pg/mL, respectively (Fig. 2B and Table S1). These results indicated that IL-8 is significantly up-regulated accompanying with HPV 16 E6 expression in lung cancer cells.
IL-8 expression levels of H1299-HPV16E6 induced by PonA were significantly higher than that of parental H1299, H1299-pIND and H1299-HPV16E6 treated with Alc or PonA after 24 hours. (A) RNA was isolated and subjected to RT-PCR analysis using specific primers to IL-8. HPV 16 E6-containing SiHa cervical cancer cells were used as positive control (lane 10). (B) IL-8 levels in cell culture supernatants were analyzed by ELISA (*P<0.05 by t-test).
MMP-2 and MMP-9 Expression and Activities are Up-regulated in HPV16 E6-transfected H1299 Cells
As shown in Figure 3A, both MMP-2 and MMP-9 RNA levels of H1299-HPV16E6 under PonA induction was significantly higher than other counterparts (Fig. 3A). We next examined the activities of MMP-2 and MMP-9 by zymography because activities of MMPs family proteins require processing and may not parallel to their protein expression levels. Zymographic results demonstrated that MMP-2 and MMP-9 activities were significantly increased accompanied with E6 expressions (Fig. 3, B and C). Both the increased ratios of MMP-2 and MMP-9 (at about 1.6 folds) were comparable with their protein expression levels. Results from ELISA analysis also revealed that both the secretory MMP-2 and MMP-9 levels were significantly elevated to about 1.6∼1.7 folds in PonA-induced H1299-HPV16E6 cells (MMP-2∶217.08±15.48 ng/mL; MMP-9∶31.05±3.70 ng/mL), compared with that under Alc treatment (MMP-2∶138.65±16.22 ng/mL; MMP-9∶18.62±1.35 ng/mL, Figure 3D and Table S2). The above results suggested that basal HPV 16 E6 expression up-regulates MMPs expression. Taken the results together, it suggestes that the RNA, proteins and activities of MMP-2 and MMP-9 are significantly up-regulated by HPV 16 E6 in H1299 cells.
Expressions and activities of MMP-2 and MMP-9 in H1299-HPV16E6 induced by PonA were significantly higher than that of parental H1299, H1299-pIND and H1299-HPV16E6 treated with Alc or PonA after 24 hours. (A) RNA was isolated and subjected to RT-PCR analysis using specific primers to MMP-2 and MMP-9. (B) MMP-2 and MMP-9 activities in the culture supernatants were determined by Zymogram. HPV 16 E6-containing SiHa cervical cancer cells were used as positive control (lane 10). The quantitated results for MMP activities in (B) were shown in (C). (D) Levels of MMP-2 and MMP-9 in cell culture mediate was respectively analyzed by MMP-2- and MMP-9- specific ELISA kit (*P<0.05 by t-test).
MMP-2 and MMP-9 Expressions are Up-regulated by HPV16-induced IL-8
To verify whether the HPV 16 E6-induced IL-8 was responsible for the increased MMP-2 and MMP-9 expressions, MMPs levels in HPV 16 E6-expressing cells were further examined under the combined treatment of IL-8 siRNA to antagonize its transcription and specific antibodies to neutralize the activities. As shown in Figure 4, both MMP-2 and MMP-9 expressions were decreased when HPV-induced IL-8 was inhibited. These results suggest that MMPs up-regulation in HPV16-infected lung cancer cells is at least in part mediated by IL-8.
H1299-HPV16E6 cells were cultured in RPMI 1640 with or without 5 uM PonA and 100% Alc for 24 hours, followed by transfecting with IL-8 siRNA (lane 3 & 4) in the presence of 1 ug or 10 ug IL-8 antibodies for 6 hours to inhibit HPV-induced IL-8. MMP-2 and MMP-9 RNA was then examined by RT-PCR after 48 hours of further incubation.
Discussion
The epidemiology of lung cancer remains partially unresolved since vast majority of smokers do not develop such tumors while at least 10–15% of lung cancers occur in non smokers [25]. Thus, factors other than smoking may also have an impact as etiological and risk factors for lung cancer. Our previous studies suggested that HPV may be involved in lung cancer development through up-regulating the expressions of IL-6, IL-17 and the anti-apoptotic Mcl-1, and result in promotion of cancer cell growth [8], [9]. In addition to inactivating p53 tumor suppressors and promoting the expressions of cell proliferation proteins, HPV infection is also associated with increased tissue angiogenesis mediated by inducing the expression of various pro-angiogenic molecules including IL-8 and MMPs in cervical cancer [15], [26]–[30]. Accordingly, the goal of the present study was to determine whether HPV infection in lung adenocarcinoma cells can promote the expression of angiogenesis- and metastasis- related proteins, including IL-8 and MMPs, to make the transformed cells equipped with angiogenic and metastatic characteristics.
Our results demonstrate that HPV E6 antigens alone significantly up-regulate IL-8 expression (Fig. 2 & Table S1). In addition, not only the expression of MMP-2 and MMP-9, but also their corresponding gelatinase activities are increased (Fig. 3 & Table S2). Our data further reveal that the increased MMP-2 and MMP-9 expressions are mediated by the HPV E6-induced IL-8 because the MMPs levels are reduced when HPV-induced IL-8 is inhibited by combined treatment of IL-8 siRNA and neutralizing antibodies (Fig. 4). These observations support previous studies in which IL-8 is up-regulated following expression of HPV 16 E6/E7 in primary foreskin keratinocytes and cervical cancer cell lines [15], [31]. Besides, our results also indicate that, in addition to cell proliferation-related machinery, HPV infection can promote the expression and activities of angiogenic and metastatic molecules in lung cancer cells. The combination of growth-promoting, angiogenic and metastatic machineries further confer the malignant and tumorigenic potentials on the infected cancer cells.
Inactive p53 and high-risk HPV infection are both associated with changes in angiogenesis by a p53-dependent pathway [26]. The increased angiogenesis and down-regulated apoptosis further facilitate tumor progression. On the contrary, HPV-regulated angiogenesis can alternatively occur through a p53-independent mechanism: the induction of VEGF transcription by HPV E6 remains equal in p53−/− fibroblasts [32]. The present observation that HPV 16 E6 in p53−/− IL-6-null H1299 cells can significantly up-regulate pro-angiogenic MMPs expressions through IL-8 and our previous reports in which E6 can induce IL-17 expressions [9] indicate that HPV 16 E6 can mediate angiogenic promotion and antiapoptotic effects through cytokines by a p53-independent mechanism.
IL-8 is a potent angiogenic factor and autocrine growth factor in several human cancers [11], which is associated with metastasis [12]–[14]. IL-8 promotes human lung cancer growth through its angiogenic properties [33]. Its autocrine and paracrine function has been shown to play an important role in angiogenesis, tumor growth, and metastasis [24], [25], [34], [35]. Recent reports suggest that IL-8 regulates the expression and activity of MMP-9 in human prostate carcinoma cell lines [24]. Moreover, IL-8 blocking antibody is able to down-regulate MMP-9 expression and activity in orthotopic bladder cancer xenografts [36]. IL-8 can also stimulate neutrophils to release stored MMP-9, which has been shown to exert positive feedback control by cleavage of IL-8, thus increasing its chemotactic activity for neutrophils [37], [38]. Expression of IL-8 by human melanoma cells up-regulates MMP-2 activity to increase tumor growth and metastasis [14]. IL-8 promotes the invasiveness of endometrial stromal cells to the extracellular matrix by upregulating MMP-2 and MMP-9 activity [39]. Furthermore, IL-8 is involved in the degradation of extracellular matrix by MMP-2 and MMP-9 activity, leading to endothelial cell migration, invasion and capillary tube organization [25]. Our results, in support of the above findings, suggest that IL-8 may act as an autocrine and/or paracrine angiogenic factor for HPV16 E6-expressing H1299 cells by enhancing MMP-2 and MMP-9 expression.
Although abundant evidences demonstrate that IL-8 expression is induced by HPV infection in several cancer cell lines, controversial results still exist. Huang et al. reported that HPV 16 E6 down-regulates IL-8 expression through NF-kB pathway in primary keratinocytes, which is contradictory to our observations [40]. Two possible factors may explain this discrepancy: First of all, the cell model in their study is primary cell while ours is lung adenocarcinoma. The nature or difference of these 2 cell models, and thus the regulatory machineries and gene compositions, may result in the conflicting results. Secondly, the cell-type specific gene expression patterns in response to a particular pathogen may lead to the differential results. Nevertheless, HPV 16 E6 has been reported to contribute to the induction of several pro-angiogenic factors, including IL-8, in human foreskin keratinocytes [30] and human umbilical vein endothelial cells [15]. Particularly, our observation supports a recent report from Li et al. [41], in which HPV 16 E6 overexpression in lung cancer cells significantly promotes angiogenesis via enhancing the expression of several pro-angiogenic factors such as HIF-1a, VEGF and IL-8.Earlier studies suggest that IL-8-mediated inhibition of apoptosis could be dependent or independent of Bcl-2 expression [25], [42]. IL-8 might regulate angiogenesis by modulating the anti-apoptosis pathway of CXCR1- and CXCR2- expressing endothelial cells [25]. Additionally, it is known that the anti-apoptotic Mcl-1 can also be up-regulated at both transcript and protein levels by IL-8 [43], and the loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis [44]. Some studies have demonstrated that IL-8 can regulate polymorphonuclear leukocytes apoptosis by up-regulating Mcl-1 antiapoptotic effect [42]–[45]. These data may suggest that IL-8 might also have anti-apoptotic activity, as the scenario of IL-6, by promoting Mcl-1 expression through its autocrine and/or paracrine functions by CXCR1 and/or CXCR2 receptor in HPV16 E6- expressing H1299 cells. However, this speculation awaits further study.
In summary, our results reveal that the HPV 16 E6 significantly up-regulates pro-angiogenic MMP-2 and MMP-9 expressions through inducing IL-8 in a p53-independent manner. The present study suggests that HPV infection may be involved in angiogenic promotion mediated by IL-8, MMP-2, MMP-9 up-regulation in lung adenocarcinoma. Combining the present study and our previous data [8], [9], a model for high-risk HPV infection to potentiate the proliferating and angiogenic activities in lung cancer cells is proposed as depicted in Fig. 5. First of all, HPV infection induces IL-6 and Mcl-1 expression, which subsequently promotes lung tumorigenesis. Therefore, the HPV-related lung tumorigenesis is suggested to be associated with the up-regulation of anti-apoptotic Mcl-1 expression mediating by IL-6 (black pathway in Fig. 5) [8]. In addition, HPV 16 E6 oncoproteins induce IL-17 levels which subsequently promote the expression of anti-apoptotic protein Mcl-1 bypassing the IL-17-downstream IL-6 molecules through PI3K pathway in a p53-independent manner. The HPV-mediated IL-17 and Mcl-1-dependent anti-apoptotic effects may play an important role in HPV-associated lung tumorigenesis (red pathway in Fig. 5) [9]. Thirdly, HPV-induced IL-8 may act as an autocrine and/or paracrine angiogenic factor which augments MMPs production and activities (blue pathway in Fig. 5). In addition, we speculate that HPV infection may elicit a cytokine cascade by up-regulating IL-6 and IL-8 production through inducing IL-17, which is known to induce the release of IL-6 and IL-8 through the p38 and ERK MAPK pathway in human bronchial epithelial cells (green pathway in Fig. 5) [46], [47]. However, this speculation needs further investigation. Taken altogether, our studies provide the evidence of an association between inflammation and HPV infection in lung cancer. The cytokines induced by HPV may work together and contribute to potentiate the proliferation and angiogenesis required for lung tumorigenesis.
HPV-related lung tumorigenesis is suggested to be associated with the up-regulation of anti-apoptotic Mcl-1 expression mediating by IL-6. In addition, HPV up-regulates IL-17 which subsequently promotes Mcl-1 expression bypassing the IL-17 downstream IL-6 molecules. HPV-induced IL-8 may act as an angiogenic factor which augments MMPs production and activities.
Supporting Information
Table S1.
IL-8 levels were induced in HPV 16 E6-transfected H1299 cells.
https://doi.org/10.1371/journal.pone.0054423.s001
(DOC)
Table S2.
MMP-2 and MMP-9 levels were induced in HPV 16 E6-transfected cells.
https://doi.org/10.1371/journal.pone.0054423.s002
(DOC)
Author Contributions
Substantial contributions to conception and design of the work, acquisition of data, or analysis and interpretation of data: MYS LCF SCY CHT HL YWC LCL YHC. Drafting the article or revising it critically for important intellectual content: MYS YHC. Final approval of the version to be published: MYS YHC . Conceived and designed the experiments: MYS SCY CHT HL YWC YHC. Performed the experiments: MYS LCF SCY CHT LCL. Analyzed the data: MYS LCF SCY CHT HL YWC LCL YHC. Contributed reagents/materials/analysis tools: MYS LCF SCY CHT HL YWC LCL YHC. Wrote the paper: MYS YHC.. Conceived and designed the experiments: MYS SCY CHT HL YWC YHC. Performed the experiments: MYS LCF SCY CHT LCL. Analyzed the data: MYS LCF SCY CHT HL YWC LCL YHC. Contributed reagents/materials/analysis tools: MYS LCF SCY CHT HL YWC LCL YHC. Wrote the paper: MYS YHC.
References
- 1. Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, et al. (2003) Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60: 186–198.
- 2. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243–3256.
- 3. Folkman J, Cotran R (1976) Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 16: 207.
- 4. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.
- 5. D'Amico TA (2004) Angiogenesis in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 16: 13–18.
- 6. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, et al. (2001) The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 61: 2799–2803.
- 7. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, et al. (2007) Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 67: 10686–10693.
- 8. Cheng YW, Lee H, Shiau MY, Wu TC, Huang TT, et al. (2008) Human papillomavirus type 16/18 up-regulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer. Clin Cancer Res 14: 4705–4712.
- 9. Chang YH, Yu CW, Lai LC, Tsao CH, Ho KT, et al. (2010) Up-regulation of interleukin-17 expression by human papillomavirus type 16 E6 in nonsmall cell lung cancer. Cancer 116: 4800–4809.
- 10. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620–2627.
- 11. Smith DR, Polverini PJ, Kunkel SJ, Orringer MB, Whyte RI, et al. (1994) Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179: 1409–1415.
- 12. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ (1994) Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54: 3242–3248.
- 13. Ueda T, Shimada E, Urikawa T (1994) Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29: 423–429.
- 14. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, et al. (1997) Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151: 1105–1113.
- 15. Bequet-Romero M, Lopez-Ocejo O (2000) Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun 277: 55–61.
- 16. Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, et al. (2001) The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92: 2628–2638.
- 17. Orditura M, De Vita F, Catalano G, Infusino S, Lieto E, et al. (2002) Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 22: 1129–1135.
- 18. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, et al. (2003) Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9: 729–737.
- 19. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, et al. (1996) Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 97: 2792–2802.
- 20. Wang J, Huang M, Lee P, Komanduri K, Sharma S, et al. (1996) Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. J Interferon Cytokine Res 16: 53–60.
- 21. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, et al. (2000) Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 162: 1957–1963.
- 22. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, et al. (2000) Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6: 2104–2119.
- 23. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369–3376.
- 24. Peng PL, Hsieh YA, Wang CJ, Hsu JL, Chou FP (2006) Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharm 214: 8–15.
- 25. Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123: 21S–49S.
- 26. Pillai MR, Nair MK (2000) Development of a condemned mucosa syndrome and pathogenesis of human papillomavirus-associated upper aerodigestive tract and uterine cervical tumors. Exp Mol Pathol 69: 233–241.
- 27. Garzetti GG, Ciavattini A, Lucarini G (1998) The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis: Association with 72-kilodalton metalloproteinase immunostaining. Cancer 82: 886–892.
- 28. Evander M, Frazer IH, Payne E (1997) Identification of the alpha (6) integrin as a candidate receptor for papillomaviruses. J Virol 71: 2449–2456.
- 29. Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, et al. (2001) The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 97: 223–230.
- 30. Toussaint-Smith E, Donner DB, Roman A (2004) Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23: 2988–2995.
- 31. Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, et al. (2005) Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol 86: 1291–1296.
- 32. Lopez-Ocejo O, Viloria-Petit AM, Bequet-Romero M, Rak J, Mukhopadhyay D, et al. (2000) Oncogenes and tumor angiogenesis: The HPV-16 E6 oncoprotein activate the vascular endothelial growth factor (VEGF) gen promoter in a p53 independent manner. Oncogene 19: 4611–4620.
- 33. Zhu YM, Webster SJ, Flower D, Woll PJ (2004) Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 91: 1970–1976.
- 34. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, et al. (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96: 34–40.
- 35. Singh RK, Varney ML, Ino K, Vose JM, Bierman PJ, et al. (2000) Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin’s lymphoma patients. Exp Hematol 28: 499–507.
- 36. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, et al. (2003) Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9: 3167–3175.
- 37. Atkinson JJ, Senior RM (2003) Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 28: 12–24.
- 38. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G (2000) Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96: 2673–2681.
- 39. Mulayim N, Savlu A, Guzeloglu-Kayisli O, Kayisli UA, Arici A (2004) Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8. Fertil Steril 81: 904–911.
- 40. Huang SM, McCance DJ (2002) Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 76: 8710–8721.
- 41. Li G, He L, Zhang E, Shi J, Zhang Q, et al. (2011) Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1a and VEGF expression in non-small cell lung cancer cells. Cancer Lett 311: 160–170.
- 42. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, et al. (2001) Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61: 2183–2188.
- 43. Moulding DA, Quayle JA, Hart CA, Edwards SW (1998) Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood 92: 2495–2502.
- 44. Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH (2000) The loss of Mcl-1 expression in human polymorphonuclear leukocytes promotes apoptosis. J Leuko Biol 68: 158–166.
- 45. Hu M, Miller EJ, Lin X, Simms HH (2004) Transmigration across a lung epithelial monolayer delays apoptosis of polymorphonuclear leukocytes. Surgery 135: 87–98.
- 46. Linden LM (2002) IL-17 as a potential target for modulating airway neutrophilia. Curr Pharm Des 8: 1855–1861.
- 47. Hsieh HG, Loong CC, Lin CY (2002) Interleukin-17 induces SRC/MAPK cascades activation in human renal epithelial cells. Cytokine 19: 159–174.